The British Journal of Clinical Pharmacology

Volume 28
1989

Published for
The British Pharmacological Society by
Blackwell Scientific Publications

© 1989 Blackwell Scientific Publications
Osney Mead, Oxford OX2 0EL
8 John Street, London WC1N 2ES
23 Ainslie Place, Edinburgh EH3 6AJ
3 Cambridge Center, Cambridge, Mass. 02142, USA
107 Barry Street, Carlton, Victoria 3053, Australia

Published on behalf of
The British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Scientific Publications for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $03.00 per copy is paid directly to CCC, 27 Congress Street, Salem, MA 01970, USA. 0306-5251/89 $03.00/0. (For copying beyond that permitted by Sections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to the Editor.

Typeset by Oxprint Ltd, Oxford
Printed in Great Britain
at the University Press, Cambridge

Whilst every effort is made by the publishers and editorial committee to see that no inaccurate or misleading data, opinion or statement appears in this Journal, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publishers and the editorial committee and their respective employees, officers and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement.

Contents

Number 1, July 1989

Papers

1 EEG brain mapping in evaluating the time-course of the central action of DUP 996—a new acetylcholine releasing drug: *B. Saletu, A. Darragh, P. Salmon & R. Coen*

17 The effect of pregnancy in humans on the pharmacokinetics of stable isotope labelled phenytoin: *R. G. Dickinson, W. D. Hooper, B. Wood, C. M. Lander & M. J. Eadie*

29 Effect of quinidine on the dextromethorphan *O*-demethylase activity of microsomal fractions from human liver: *F. Broly, C. Libersa, M. Lhermitte, P. Bechtel & B. Dupuis*

37 Comparison of Sawchuk-Zaske and Bayesian forecasting for aminoglycosides in seriously ill patients: *C. P. Denaro & P. J. Ravenscroft*

45 Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure: *P. H. J. M. Dunselman, B. Edgar, A. H. J. Scaf, C. E. E. Kuntze & H. Wesseling*

53 The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis: *H. H. Tsai, K. R. Lees, C. W. Howden & J. L. Reid*

61 The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa: *D. R. C. Robertson, N. D. Wood, H. Everest, K. Monks, D. G. Waller, A. G. Renwick & C. F. George*

71 Pharmacokinetics of halofantrine in man: effects of food and dose size: *K. A. Milton, G. Edwards, S. A. Ward, M.L'E. Orme & A. M. Breckenridge*

79 The effect of slow-release nicardipine on ambulatory and clinic blood pressure in mild hypertension: *J. P. Cox, J. Ryan, E. O'Brien & K. O'Malley*

83 β-adrenergic receptor responsiveness to isoprenaline in humans: concentration-effect, as compared with dose-effect evaluation and influence of autonomic reflexes: *A. Martinsson, K. Lindvall, A. Melcher & P. Hjemdahl*

95 Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of β_2-adrenoceptor blockade: *B. J. Lipworth, R. A. Brown & D. G. McDevitt*

103 The effect of theophylline on thyrotoxic tremor: *D. C. Buss, D. I. W. Phillips, M. D. Littley, R. W. Marshall, P. A. Routledge & J. H. Lazarus*

109 Failure of ethamsylate to reduce aspirin-induced gastric mucosal bleeding in humans: *T. K. Daneshmend, A. G. Stein, N. K. Bhaskar & C. J. Hawkey*

Short reports

113 Adverse drug reactions: a hospital pharmacy-based reporting scheme: *P. A. Winstanley, L. E. Irvin, J. C. Smith, M. L'E. Orme & A. M. Breckenridge*

117 The pharmacokinetics of lamotrigine (BW430C) in healthy subjects with unconjugated hyperbilirubinaemia (Gilbert's Syndrome): *J. Posner, A. F. Cohen, G. Land, C. Winton & A. W. Peck*

121 Evaluation of the gastric absorption and emptying of drugs under various pH conditions using a simple intubation method: application to diclofenac: *N. Vidon, A. Pfeiffer, J. Godbillon, M. Rongier, S. Gauron, J. Hirtz, J. J. Bernier & J. P. Dubois*

Number 2, August 1989

Papers

125 L-648,051, a novel cysteinyl-leukotriene antagonist is active by the inhaled route in man: *J. M. Evans, N. C. Barnes, J. T. Zakrzewski, D. G. Sciberras, E. G. Stahl, P. J. Piper & J. F. Costello*

137 Individualised aminoglycoside dosage based on pharmacokinetic analysis is superior to dosage based on physician intuition at achieving target plasma drug concentrations: *E. J. Begg, H. C. Atkinson, G. M. Jeffery & N. W. Taylor*

143 Lack of effect of cimetidine on the pharmacokinetics of R(−)- and S(+)-ibuprofen: *A. M. Evans, R. L. Nation & L. N. Sansom*

151 Stereoselectivity in the urinary excretion of the mercapturates of (R−) and (S−) α-bromoisovalerylurea in man: *J. M. Te Koppele, C. Schipper, D. D. Breimer & G. J. Mulder*

155 Neuromuscular blockade with vecuronium in paediatric patients with burn injury: *A. K. Mills & J. A. Martyn*

Short reports

161 Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine: *J. O. Atiba, T. F. Blaschke & G. R. Wilkinson*

166 Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes *in vitro*: *D. J. Back, P. Stevenson & J. F. Tjia*

171 The effect of roxatidine acetate and cimetidine on hepatic drug clearance assessed by simultaneous administration of three model substrates: *E. Tanaka & K. Nakamura*

175 Plasma protein binding of frusemide in liver disease: effect of hypoalbuminaemia and hyperbilirubinaemia: *A. Viani, M. Carrai & G. M. Pacifici*

179 Divided dose kinetics of mefloquine in man: *G. Franssen, B. Rouveix, J. Lebras, J. Bauchet, F. Verdier, C. Michon & F. Bricaire*

185 Co-administration of ciprofloxacin and cyclo-

sporin: lack of evidence for a pharmacokinetic interaction: *K. K. C. Tan, A. K. Trull & S. Shawket*
188 Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations: *M. Dryjski, D. E. Schneider, P. Mojaverian, Be-Sheng Kuo & T. D. Bjornsson*
193 Effect of diclofenac on prostaglandin E and hyaluronic acid production by human synovial fibroblasts stimulated with interleukin-1: *F. A. Meyer, I. Yaron, V. Mashiah & M. Yaron*
197 Pharmacokinetics of quinine in African children suffering from kwashiorkor: *L. A. Salako, A. Sowunmi & F. O. Akinbami*
202 Pharmacokinetics of intravenous buprenorphine in children: *K. T. Olkkola, E.-L. Maunuksela & R. Korpela*
205 Local anaesthetic cream for the alleviation of pain during venepuncture in Tanzanian schoolchildren: *U. Hellgren, C. M. Kihamia, Z. Premji & K. Danielson*

Letters to the Editors
207 Potential artifacts in the use of caffeine to determine acetylation phenotype: *B. Lorenzo & M. M. Reidenberg*
208 Drug treatment of intermittent claudication: *K.-H. Labs*
210 Drug treatment of intermittent claudication: *H. A. Cameron, P. C. Waller & L. E. Ramsay*

Proceedings
211 Proceedings of the British Pharmacological Society (University of Bristol, 5–7 April 1989)

Number 3, September 1989

Papers
249 The haemodynamic and hormonal responses after clonidine occur independently of sedation in essential hypertension: *J. S. Kooner, W. S. Peart & C. J. Mathias*
257 A comparison of the effects of human alpha calcitonin gene-related peptide and glyceryl trinitrate on regional blood velocity in man: *N. J. MacDonald, L. Butters, D. J. O'Shaughnessy, A. J. Riddell & P. C. Rubin*
263 The effect of a single oral dose of pergolide on intraocular pressure and pupil diameter: *M. R. Al-Sereiti, R. F. P. Quik & P. Turner*
269 Comparison of different dose regimes of aminohydroxypropylidene-1, 1-bisphosphonate (APD) in hypercalcaemia of malignancy: *J. R. E. Davis & D. A. Heath*
275 Prediction of creatinine clearance from plasma creatinine: comparison of five formulae: *M. Robertshaw, K. N. Lai & R. Swaminathan*
281 Pharmacokinetics of the thromboxane A_2 receptor antagonist sulotroban (BM 13.177) in renal failure: *C. Piper, Ch. Staiger, Y. Jumeau-Ziemendorff, V. Uebis, B. Kaufmann & K. Stein*
289 Pharmacokinetics of (−)-folinic acid after oral and intravenous administration of the racemate: *P. O. Greiner, J. Zittoun, J. Marquet & J. M. Cheron*
297 Effect of liver disease on dextromethorphan oxidation capacity and phenotype: a study in 107 patients: *D. Larrey, G. Babany, M. Tinel, E. Freneaux, G. Amouyal, F. Habersetzer, P. Letteron & D. Pessayre*
305 Population pharmacokinetics of tobramycin: *L. Aarons, S. Vozeh, M. Wenk, Ph. Weiss & F. Follath*
315 Effects of a 5-hydroxytryptamine$_3$ receptor antagonist (ICS 205-930) on colonic motor activity in healthy men: *G. Stacher, G. Gaupmann, C. Schneider, G. Stacher-Janotta, G. Steiner-Mittelbach, Th.-A. Abatzi & H. Steinringer*
323 A double-blind dose ranging study of BRL 24924 and metoclopramide on lower oesophageal sphincter pressure in healthy volunteers: *C. S. Robertson, S. J. Ledingham, S. M. Cooper & D. F. Evans*
329 The effect of oxytocin on basal and pethidine-induced delayed gastric emptying: *O. U. Petring*
333 Novel medicines marketed in the UK (1960–87): *Y. Lis & S. R. Walker*

Short reports
345 The benefits of prescription information leaflets (2): *S. Gibbs, W. E. Waters & C. F. George*
352 Kinetics of digoxin and anti-digoxin antibody fragments during treatment of digoxin toxicity: *A. J. Sinclair, D. S. Hewick, P. C. Johnston, I. H. Stevenson & M. Lemon*
357 Serum binding of nifedipine and verapamil in patients with ischaemic heart disease on monotherapy: *D. O. Rumiantsev, V. K. Piotrovskii, V. I. Metelitsa, I. D. Slastnikova, S. Yu. Martsevich & E. V. Kokurina*
362 Calcium channel antagonists and cyclosporine metabolism: *in vitro* studies with human liver microsomes: *J. F. Tjia, D. J. Back & A. M. Breckenridge*
366 Yohimbine increases human salivary secretion: *E. Chatelut, Y. Rispail, M. Berlan & J. L. Montastruc*
369 A controlled clinical trial on the cardiovascular effects of single doses of pseudoephedrine in hypertensive patients: *S. S. Chua, S. I. Benrimoj, R. D. Gordon & G. Williams*

Number 4, October 1989

Papers

373 The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction: *C. Ged, J. M. Rouillon, L. Pichard, J. Combalbert, N. Bressot, P. Bories, H. Michel, P. Beaune & P. Maurel*

389 Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes: *M. D. Coleman, A. M. Breckenridge & B. K. Park*

397 Atrial natriuretic peptide and urinary prostaglandins in man: *D. Benzoni, J. Geoffroy, B. Waeber, H. R. Brunner, J. Biollaz & J. Sassard*

403 Inhibition of gastric secretion following single morning or twice daily oral administration of sufotidine to volunteers: *D. A. Johnston & K. G. Wormsley*

409 The effect of phentolamine on basal and pethidine-induced inhibition of gastric emptying in healthy volunteers: *O.U. Petring*

415 Lisinopril dose-response relationship in essential hypertension: *H. J. Gomez, V. J. Cirillo, J. A. Sromovsky, E. S. Otterbein, W. C. Shaw, J. E. Rush, S. G. Chrysant, A. H. Gradman, A. S. Leon, E. P. MacCarthy, E. B. Nelson, J. Pool & A. Vedin*

421 *N*-acetylcysteine fails to attenuate haemodynamic tolerance to glyceryl trinitrate in healthy volunteers: *J. C. Hogan, M. J. Lewis & A. H. Henderson*

427 Comparison of the immediate and long-term effects of captopril and isosorbide dinitrate as adjunctive treatment in mild heart failure: *N. P. F. Wilkes, E. Barin, R. Hoschl, G. S. Stokes & G. I. C. Nelson*

435 A dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D_2-receptor agonist: *G. Acton & C. Broom*

443 A comparison of the ocular hypotensive effect of 0.025% bromocriptine and 0.25% timolol eye drops in normal human volunteers: *M. R. Al-Sereiti, R. L. Coakes, D. P. D. O'Sullivan & P. Turner*

449 Salicylate pharmacokinetics in patients with rheumatoid arthritis: *S. G. Owen, M. S. Roberts, W. T. Friesen & H. W. Francis*

463 Pharmacokinetics of dextropropoxyphene and nordextropropoxyphene in young and elderly volunteers after single and multiple dextropropoxyphene dosage: *R. J. Flanagan, A. Johnston, A. S. T. White & P. Crome*

471 Bioelectrical impedance modelling of gentamicin pharmacokinetic parameters: *B. J. Zarowitz, A. M. Pilla & E. L. Peterson*

Short reports

479 Gentamicin volume of distribution as a power function of body weight: *F. Keller*

482 Structural requirements for bioactivation of anticonvulsants to cytotoxic metabolites *in vitro*: *R. J. Riley, N. R. Kitteringham & B. K. Park*

488 Effect of oxpentifylline on blood viscosity and cerebral blood flow in man: *M. M. Brown*

Letters to the Editors

493 An observation on the ethnic uniqueness of the debrisoquine and sparteine antimodes: a study in the Ngawbé Guaymí Amerindians of Panamá: *T. D. Arias & L. F. Jorge*

494 Nabilone as effective therapy for intractable nausea and vomiting in AIDS: *S. T. Green, D. Nathwani, D. J. Goldberg & D. H. Kennedy*

495 Psychomotor effects of ketorolac: *U. Saarialho-Kere*

Number 5, November 1989

Review

497 Prodrugs: *D. G. Waller & C. F. George*

Papers

509 Slow release nifedipine plus atenolol in chronic stable angina pectoris: *V. F. Challenor, D. G. Waller, A. G. Renwick & C. F. George*

517 Concentration-effect relationships and individual responses to doxazosin in essential hypertension: *R. Donnelly, H. L. Elliott, P. A. Meredith & J. L. Reid*

527 CNS-related subjective symptoms during treatment with β_1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies: *E. Dimenäs, C. Dahlöf, B. Olofsson & I. Wiklund*

535 Garlic, onions and cardiovascular risk factors. A review of the evidence from human experiments with emphasis on commercially available preparations: *J. Kleijnen, P. Knipschild & G. Ter Riet*

545 The effect of the circadian rhythm of vagal activity on bronchomotor tone in asthma: *J. F. J. Morrison & S. B. Pearson*

551 Differential effect of continuous administration of β-adrenoceptor antagonists on antipyrine and phenytoin clearance: *H. Perrild, L. Kayser, H. E. Poulsen, L. Skovsted, B. Jørgensen & J. Mølholm Hansen*

555 Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype: *A. S. Gross, G. Mikus, C. Fischer, R. Hertrampf, U. Gundert-Remy & M. Eichelbaum*

567 Dose-dependent effect and side-effect of prostaglandin E_1 in erectile dysfunction: *P. Schramek & M. Waldhauser*

573 Differential effect of aspirin on thromboxane

and prostaglandin biosynthesis in man: *J. M. Ritter, J. R. Cockcroft, H. S. Doktor, J. Beacham & S. E. Barrow*
581 Enhanced gastric mucosal bleeding with doses of aspirin used for prophylaxis and its reduction by ranitidine: *G. K. Kitchingham, P. J. Prichard, T. K. Daneshmend, R. P. Walt & C. J. Hawkey*
587 Differences in the serum binding determinants of isradipine and darodipine — consequences for serum protein binding in various diseases: *J. L. Pinquier, S. Urien, P. Chaumet-Riffaud & J. P. Tillement*
593 Factors affecting free (unbound) lignocaine concentration in suspected acute myocardial infarction: *P. A. Routledge, W. W. Stargel, A. Barchowsky, G. S. Wagner & D. G. Shand*
599 Morphine metabolism in children: *I. A. Choonara, P. McKay, R. Hain & A. Rane*

Short reports
605 Effect of short-acting nitroglycerin on heart rate: evaluation by a self-monitoring device: *J. T. Lahtela & E. A. Sotaniemi*
608 The effect of oral cilazapril and prazosin on the constrictor effects of locally infused angiotensin I and noradrenaline in human dorsal hand veins: *G. G. Belz, C. Beerman, J. Schloos & C. H. Kleinbloesem*
612 The influence of food on the pharmacokinetics of 'biphasic' nifedipine at steady state in normal subjects: *G. H. Rimoy, J. R. Idle, N. K. Bhaskar & P. C. Rubin*
616 Bioavailability of intranasal metoclopramide: *M. J. Ward, D. C. Buss, J. Ellershaw, A. Nash & P. A. Routledge*

Letter to the Editors
619 The value of therapeutic drug monitoring to the practising physician — an hypothesis needing sensible application!: *I. D. Watson & A. H. Thomson*

Number 6, December 1989

Review
621 The effects of food on drug bioavailability: *P. A. Winstanley & M. L'E. Orme*

Papers
629 Interindividual and interethnic differences in the demethylation and glucuronidation of codeine: *Q. Y. Yue, J.-O. Svensson, C. Alm, F. Sjöqvist & J. Säwe*
639 Codeine *O*-demethylation co-segregates with polymorphic debrisoquine hydroxylation: *Q. Y. Yue, J.-O. Svensson, C. Alm, F. Sjöqvist & J. Säwe*
647 Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism – histograms and probit plots: *P. R. Jackson, G. T. Tucker & H. F. Woods*
655 Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism – hypothesis testing: *P. R. Jackson, G. T. Tucker & H. F. Woods*
663 Altered adrenoceptor responsiveness during adrenaline infusion but not during mental stress; differences between receptor subtypes and tissues: *P. T. Larsson, A. Martinsson, G. Olsson & P. Hjemdahl*
675 The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate: *N. Ferry, N. Bernard, N. Pozet, E. Gardes, G. Cuisinaud, M. Labeeuw, P. Y. Zech & J. Sassard*
683 Frusemide, ACE inhibition, renal dopamine and prostaglandins: acute interactions in normal man: *T. M. MacDonald, K. Craig & M. L. Watson*
695 Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers: *R. O. Day, G. G. Graham, D. Bieri, M. Brown, D. Cairns, G. Harris, J. Hounsell, S. Platt-Hepworth, R. Reeve, P. N. Sambrook & J. Smith*
703 Benorylate hydrolysis by human plasma and human liver: *F. M. Williams, U. Moore, R. A. Seymour, E. M. Mutch, E. Nicholson, P. Wright, H. Wynne, P. G. Blain & M. D. Rawlins*
709 Bronchodilator action of inhaled fenoterol and ipratropium in normal subjects: a teaching exercise for medical students: *R. G. Taylor, J. Maclagan & D. G. Cook*

Short reports
715 Lithium inhibits human sperm motility *in vitro*: *N. T. Raoof, R. M. Pearson & P. Turner*
718 The pharmacokinetics of xamoterol in liver disease: *D. P. Nicholls, A. J. Taggart, J. P. McCann, W. Bastain & R. G. Shanks*
722 The bioavailability of intranasal lignocaine: *J. M. Scavone, D. J. Greenblatt & D. G. Fraser*
725 β-adrenoceptor responses to inhaled salbutamol in the elderly: *B. J. Lipworth, B. F. Tregaskis & D. G. McDevitt*

Proceedings
731 Proceedings of the British Pharmacological Society (University of Leeds, 12–14 July 1989)

Indexes
755 Author and subject indexes to Volume 28

Supplement 1, 1989

1S Editorial comment: *D. B. Barnett & A. Breckenridge*

3S The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart: *H. M. Snow*

15S Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure: *S. J. S. Virk & M. K. Davies*

23S Xamoterol, a β_1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure: *H. F. Marlow*

31S Treatment of congestive heart failure—state of the art and future trends: *W. W. Parmley*

41S Focus on diastolic dysfunction: a new approach to heart failure therapy: *H. Pouleur, C. Hanet, O. Gurné & M. F. Rousseau*

53S Long-term studies with xamoterol in heart failure: *D. G. Waller*

59S The management of heart failure and the scope for new therapies: what role for xamoterol?: *R. W. F. Campbell*

65S The effect of age and renal impairment on the pharmacokinetics of xamoterol: *W. Bastain & H. F. Marlow*

67S Xamoterol in mild to moderate heart failure: a subgroup analysis of patients with cardiomegaly but no concomitant angina pectoris: *The European 'Corwin' Study Group*

70S Effect of xamoterol on peripheral blood vessels in healthy subjects: *D. E. Fitzgerald*

73S Effect of β-adrenoceptor agents on the blood flow in carotid arteries in normal volunteers: *D. E. Fitzgerald & J. D. Harry*

75S The effects of age, sex and treatment with xamoterol on exercise capacity in patients with heart failure: *L. A. France, F. L. Green & H. M. Snow*

78S The cardiovascular pharmacology of xamoterol, cicloprolol, prenalterol and pindolol in the anaesthetised dog: *S. E. Hadfield, S.-J. Slee & H. M. Snow*

82S The efficacy and safety of chronic oral administration of xamoterol to patients with severe heart failure treated with ACE inhibitors: *H. Pouleur, C. Hanet & M. F. Rousseau*

84S Contrasting effects of single doses of pindolol and xamoterol on left ventricular diastolic function: *M. R. Rousseau, H. Pouleur, J. C. Debaisieux, C. Van Eyll & A. A. Charlier*

86S Long-term efficacy of xamoterol (a β_1-adrenoceptor partial agonist) in patients with mild to moderate heart failure: *E. Vigholt Sørenson, O. Faergeman, M. A. E. Day & H. M. Snow*

89S Effects of xamoterol on sodium excretion in volunteers: *P. Y. Zech, N. Pozet, M. A. E. Day, H. M. Snow, O. Madonna & A. Hadj-Aissa*

Supplement 2, 1989

Papers

93S Opening remarks: *P. S. Sever*

95S Why are converting enzyme inhibitors vasodilators?: *P. M. Vanhoutte, W. Auch-Schwelk, M. L. Biondi, R. R. Lorenz, V. B. Schini & M. J. Vidal*

105S Estimation of regional metabolism and production of angiotensins in hypertensive subjects: *M. A. D. H. Schalekamp, P. J. J. Admiraal & F. H. M. Derkx*

115S Comparisons *in vitro*, *ex vivo*, and *in vivo* of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE): *D. W. Cushman, F. L. Wang, W. C. Fung, G. J. Grover, C. M. Harvey, R. J. Scalese, S. L. Mitch & J. M. DeForrest*

133S Pharmacokinetics of angiotensin converting enzyme inhibitors: *M. Burnier, B. Waeber, J. Nussberger & H. R. Brunner*

141S Angiotensin and the remodelling of the myocardium: *K. T. Weber & J. S. Janicki*

151S Effects of antihypertensive agents on endothelium-dependent and endothelium-independent relaxations: *P. J. Shultz & L. Raij*

159S ACE inhibitors in acute and chronic ischaemia: current status and future promise: *E. H. Sonnenblick, M. Zhao, C. Eng, T. H. LeJemtel, S. M. Factor, J. Capasso & P. Anversa*

167S Relationships between structure and effects of ACE inhibitors: comparative effects in myocardial ischaemic/reperfusion injury: *K. Przyklenk & R. A. Kloner*

177S Angiotensin converting enzyme inhibition and cerebral circulation—a review: *G. Waldemar & O. B. Paulson*

183S Clinical implications for therapy: possible cardioprotective effects of ACE inhibition: *V. J. Dzau*

189S Closing remarks: *P. Corvol*